Click to Enlarge
Facebook
Twitter
The Financial Times focuses on the pause of the Johnson and Johnson vaccine rollout in Europe as US agencies review concerns over rare blood clots – similar to those seen in the AstraZeneca jab. The US review is due to be complete in “a matter of days”, the paper says, and Johnson and Johnson took the decision itself to halt the use of its jab in Europe.